# PRIME (NCT03561961)

> Prostate Radiotherapy Comparing Moderate and Extreme Hypo-fractionation (PRIME Trial)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03561961
- Phase: NA
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Tata Memorial Centre
- Conditions: Prostate Adenocarcinoma
- Interventions: Moderate Hypo-fractionation; Extreme Hypo-fractionation
- Enrollment: 526
- Primary outcome: Biochemical Failure free Survival (BFFS)

## Indexed commentary on PRIME so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=prime-nct03561961